(-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells

Khan,Munawwar Ali; Hussain,Arif; Sundaram,Madhumitha Kedhari; Alalami,Usama; Gunasekera,Dian; Ramesh,Laveena; Hamza,Amina; Quraishi,Uzma

doi:10.3892/or.2015.3802

(-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells

Authors:
- Munawwar Ali Khan
- Arif Hussain
- Madhumitha Kedhari Sundaram
- Usama Alalami
- Dian Gunasekera
- Laveena Ramesh
- Amina Hamza
- Uzma Quraishi
View Affiliations

Affiliations: Department of Natural Science and Public Health, College of Sustainability Sciences and Humanities, Zayed University, Dubai, United Arab Emirates, School of Life Sciences, Manipal University, Dubai, United Arab Emirates
Published online on: February 13, 2015 https://doi.org/10.3892/or.2015.3802
Pages: 1976-1984

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There has been increasing evidence that numerous bioactive dietary agents can hamper the process of carcinogenesis by targeting epigenetic alterations including DNA methylation. This therapeutic approach is considered as a significant goal for cancer therapy due to the reversible nature of epigenetic-mediated gene silencing and warrants further attention. One such dietary agent, green tea catechin, (-)-epigallocatechin-3-gallate (EGCG) has been shown to modulate many cancer-related pathways. Thus, the present study was designed to investigate the role of EGCG as an epigenetic modifier in HeLa cells. DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibition assays were conducted, and the transcription levels of DNMT3B and HDAC1 were assessed by enzymatic activity assay and RT-PCR, respectively. Furthermore, we studied the binding interaction of EGCG with DNMT3B and HDAC1 by molecular modeling as well as promoter DNA methylation and expression of retinoic acid receptor-β (RARβ), cadherin 1 (CDH1) and death-associated protein kinase-1 (DAPK1) in EGCG-treated HeLa cells by RT-PCR and MS-PCR. In the present study, time-dependent EGCG-treated HeLa cells were found to have a significant reduction in the enzymatic activity of DNMT and HDAC. However, the expression of DNMT3B was significantly decreased in a time-dependent manner whereas there was no significant change in HDAC1 expression. Molecular modeling data also supported the EGCG-mediated DNMT3B and HDAC1 activity inhibition. Furthermore, time-dependent exposure to EGCG resulted in reactivation of known tumor-suppressor genes (TSGs) in HeLa cells due to marked changes in the methylation of the promoter regions of these genes. Overall, the present study suggests that EGCG may have a significant impact on the development of novel epigenetic-based therapy.

View Figures

View References

1	Ting AH, McGarvey KM and Baylin SB: The cancer epigenome - components and functional correlates. Genes Dev. 20:3215–3231. 2006. View Article : Google Scholar : PubMed/NCBI
2	Choi JD and Lee JS: Interplay between epigenetics and genetics in cancer. Genomics Inf. 11:164–173. 2013. View Article : Google Scholar
3	Flis S, Gnyszka A and Flis K: DNA methyltransferase inhibitors improve the effect of chemotherapeutic agents in SW48 and HT-29 colorectal cancer cells. PLoS One. 27:e923052014. View Article : Google Scholar
4	Geurts van Kessel A: The cancer genome: from structure to function. Cell Oncol. 37:155–165. 2014. View Article : Google Scholar
5	Tallen G and Riabowol K: Keep-ING balance: Tumor suppression by epigenetic regulation. FEBS Lett. 588:2728–2742. 2014. View Article : Google Scholar : PubMed/NCBI
6	Wee S, Dhanak D, Li H, Armstrong SA, Copeland RA, Sims R, Baylin SB, Liu XS and Schweizer L: Targeting epigenetic regulators for cancer therapy. Ann NY Acad Sci. 1309:30–36. 2014. View Article : Google Scholar : PubMed/NCBI
7	Jeong HM, Kwon MJ and Shin YK: Overexpression of cancer-associated genes via epigenetic derepression mechanisms in gynecologic cancer. Front Oncol. 4:122014. View Article : Google Scholar : PubMed/NCBI
8	Subramaniam D, Thombre R, Dhar A and Anant S: DNA methyltransferases: A novel target for prevention and therapy. Front Oncol. 4:802014. View Article : Google Scholar : PubMed/NCBI
9	Campbell RM and Tummino PJ: Cancer epigenetics drug discovery and development: The challenge of hitting the mark. J Clin Invest. 124:64–69. 2014. View Article : Google Scholar : PubMed/NCBI
10	Cantley MD and Haynes DR: Epigenetic regulation of inflammation: Progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs. Inflammopharmacology. 21:301–307. 2013. View Article : Google Scholar : PubMed/NCBI
11	Henning SM, Wang P, Carpenter CL and Heber D: Epigenetic effects of green tea polyphenols in cancer. Epigenomics. 5:729–741. 2013. View Article : Google Scholar : PubMed/NCBI
12	Yang P, He X and Malhotra A: Epigenetic targets of polyphenols in cancer. J Environ Pathol Toxicol Oncol. 33:159–165. 2014. View Article : Google Scholar : PubMed/NCBI
13	Sharma C, Nusri Q-A, Begum S, Javed E, Rizvi TA and Hussain A: (−)-Epigallocatechin-3-gallate induces apoptosis and inhibits invasion and migration of human cervical cancer cells. Asian Pac J Cancer Prev. 13:4815–4822. 2012. View Article : Google Scholar
14	Lin CH, Chao LK, Hung PH and Chen YJ: EGCG inhibits the growth and tumorigenicity of nasopharyngeal tumor-initiating cells through attenuation of STAT3 activation. Int J Clin Exp Pathol. 7:2372–2381. 2014.PubMed/NCBI
15	Siddiqui IA, Bharali DJ, Nihal M, Adhami VM, Khan N, Chamcheu JC, Khan MI, Shabana S, Mousa SA and Mukhtar H: Excellent anti-proliferative and pro-apoptotic effects of (−)-epigallocatechin-3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo. Nanomedicine. 10:1619–1626. 2014. View Article : Google Scholar : PubMed/NCBI
16	Luo HQ, Xu M, Zhong WT, Cui ZY, Liu FM, Zhou KY and Li XY: EGCG decreases the expression of HIF-1α and VEGF and cell growth in MCF-7 breast cancer cells. J BUON. 19:435–439. 2014.PubMed/NCBI
17	Butt MS, Ahmad RS, Sultan MT, Nasir Qayyum MM and Naz A: Green tea and anticancer perspectives: Updates from last decade. Crit Rev Food Sci Nutr. 55:792–805. 2015. View Article : Google Scholar
18	Yokoyama M, Noguchi M, Nakao Y, Ysunaga M, Yamasaki F and Iwasaka T: Antiproliferative effects of the major tea polyphenol, (−)-epigallocatechin gallate and retinoic acid in cervical adenocarcinoma. Gynecol Oncol. 108:326–331. 2008. View Article : Google Scholar
19	Millard CJ, Watson PJ, Celardo I, Gordiyenko Y, Cowley SM, Robinson CV, Fairall L and Schwabe JW: Class I HDACs share a common mechanism of regulation by inositol phosphates. Mol Cell. 51:57–67. 2013. View Article : Google Scholar : PubMed/NCBI
20	Jia D, Jurkowska RZ, Zhang X, Jeltsch A and Cheng X: Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature. 449:248–251. 2007. View Article : Google Scholar : PubMed/NCBI
21	Thangapandian S, John S, Lee Y, Arulalapperumal V and Lee KW: Molecular modeling study on tunnel behavior in different histone deacetylase isoforms. PLoS One. 7:e493272012. View Article : Google Scholar : PubMed/NCBI
22	Irwin JJ, Sterling T, Mysinger MM, Bolstad ES and Coleman RG: ZINC: A free tool to discover chemistry for biology. J Chem Inf Model. 52:1757–1768. 2012. View Article : Google Scholar : PubMed/NCBI
23	Grosdidier A, Zoete V and Michielin O: SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res. 39:W270–W277. 2011. View Article : Google Scholar : PubMed/NCBI
24	Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC and Ferrin TE: UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem. 25:1605–1612. 2004. View Article : Google Scholar : PubMed/NCBI
25	El-Shakankiry NH and Mossallam GI: p15 (INK4B) and E-cadherin CpG island methylation is frequent in Egyptian acute myeloid leukemia. J Egypt Natl Canc Inst. 18:227–232. 2006.
26	Suzuki M, Shigematsu H, Iizasa T, Hiroshima K, Nakatani Y, Minna JD, Gazdar AF and Fujisawa T: Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer. 106:2200–2207. 2006. View Article : Google Scholar : PubMed/NCBI
27	Yaqinuddin A, Qureshi SA, Qazi R and Abbas F: Down-regulation of DNMT3b in PC3 cells effects locus-specific DNA methylation, and represses cellular growth and migration. Cancer Cell Int. 8:132008. View Article : Google Scholar : PubMed/NCBI
28	Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H and Hirohashi S: Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis. Proc Natl Acad Sci USA. 99:10060–10065. 2002. View Article : Google Scholar : PubMed/NCBI
29	Goelden U, Ukena SN, Pfoertner S, Hofmann R, Buer J and Schrader AJ: RAR-beta(1) overexpression in chromophobe renal cell carcinoma: A novel target for therapeutic intervention? Exp Oncol. 27:220–224. 2005.PubMed/NCBI
30	Wang AG, Kim SU, Lee SH, Kim SK, Seo SB, Yu DY and Lee DS: Histone deacetylase 1 contributes to cell cycle and apoptosis. Biol Pharm Bull. 28:1966–1970. 2005. View Article : Google Scholar : PubMed/NCBI
31	Jin Y, Blue EK and Gallagher PJ: Control of death-associated protein kinase (DAPK) activity by phosphorylation and proteasomal degradation. J Biol Chem. 281:39033–39040. 2006. View Article : Google Scholar : PubMed/NCBI
32	Chang J, Nicolau MM, Cox TR, Wetterskog D, Martens JW, Barker HE and Erler JT: LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling. Breast Cancer Res. 15:R672013. View Article : Google Scholar : PubMed/NCBI
33	Capobianco E, Mora A, La Sala D, Roberti A, Zaki N, Badidi E, Taranta M and Cinti C: Separate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell line. PLoS One. 9:e955962014. View Article : Google Scholar : PubMed/NCBI
34	Al-Rayyan N, Litchfield LM, Ivanova MM, Radde BN, Cheng A, Elbedewy A and Klinge CM: 5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines. Cancer Lett. 347:139–150. 2014. View Article : Google Scholar : PubMed/NCBI
35	Thakur VS, Deb G, Babcook MA and Gupta S: Plant phytochemicals as epigenetic modulators: Role in cancer chemoprevention. AAPS J. 16:151–163. 2014. View Article : Google Scholar :
36	Jiao F, Wang X, Yan Z, Liu C, Yue Z, Li Z, Ma Y, Li Y and Wang J: Effect of dynamic DNA methylation and histone acetylation on cPouV expression in differentiation of chick embryonic germ cells. Stem Cells Dev. 22:2725–2735. 2013. View Article : Google Scholar : PubMed/NCBI
37	Herranz M and Esteller M: DNA methylation and histone modifications in patients with cancer: Potential prognostic and therapeutic targets. Methods Mol Biol. 361:25–62. 2007.
38	Oyer JA, Chu A, Brar S and Turker MS: Aberrant epigenetic silencing is triggered by a transient reduction in gene expression. PLoS One. 4:e48322009. View Article : Google Scholar : PubMed/NCBI
39	Zopf S, Ocker M, Neureiter D, Alinger B, Gahr S, Neurath MF and Di Fazio P: Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines. BMC Cancer. 12:3862012. View Article : Google Scholar : PubMed/NCBI
40	Zhu WG and Otterson GA: The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents. 3:187–199. 2003. View Article : Google Scholar : PubMed/NCBI
41	Vendetti FP and Rudin CM: Epigenetic therapy in non-small-cell lung cancer: Targeting DNA methyltransferases and histone deacetylases. Expert Opin Biol Ther. 13:1273–1285. 2013. View Article : Google Scholar : PubMed/NCBI
42	Ben Gacem R, Hachana M, Ziadi S, Ben Abdelkarim S, Hidar S and Trimeche M: Clinicopathologic significance of DNA methyltransferase 1, 3a, and 3b overexpression in Tunisian breast cancers. Hum Pathol. 43:1731–1738. 2012. View Article : Google Scholar : PubMed/NCBI
43	Girault I, Tozlu S, Lidereau R and Bièche I: Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res. 9:4415–4422. 2003.PubMed/NCBI
44	Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y and Sasaki H: Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 97:1172–1179. 2001. View Article : Google Scholar : PubMed/NCBI
45	Qu Y, Mu G, Wu Y, Dai X, Zhou F, Xu X, Wang Y and Wei F: Overexpression of DNA methyltransferases 1, 3a, and 3b significantly correlates with retinoblastoma tumorigenesis. Am J Clin Pathol. 134:826–834. 2010. View Article : Google Scholar : PubMed/NCBI
46	Müller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies J, Winzer KJ, Dietel M, Weichert W and Denkert C: Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer. 13:2152013. View Article : Google Scholar :
47	Santoro F, Botrugno OA, Dal Zuffo R, et al: A dual role for Hdac1: Oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood. 121:3459–3468. 2013. View Article : Google Scholar : PubMed/NCBI
48	Yang H, Salz T, Zajac-Kaye M, Liao D, Huang S and Qiu Y: Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators. FASEB J. 28:4265–4279. 2014. View Article : Google Scholar : PubMed/NCBI
49	Fazi F, Travaglini L, Carotti D, et al: Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo. Oncogene. 24:1820–1830. 2005. View Article : Google Scholar : PubMed/NCBI
50	Shu L, Khor TO, Lee JH, Boyanapalli SS, Huang Y, Wu TY, Saw CL, Cheung KL and Kong AN: Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells. AAPS J. 13:606–614. 2011. View Article : Google Scholar : PubMed/NCBI
51	Moseley VR, Morris J, Knackstedt RW and Wargovich MJ: Green tea polyphenol epigallocatechin 3-gallate, contributes to the degradation of DNMT3A and HDAC3 in HCT 116 human colon cancer cells. Anticancer Res. 33:5325–5333. 2013.PubMed/NCBI
52	Fan H, Zhang R, Tesfaye D, Tholen E, Looft C, Hölker M, Schellander K and Cinar MU: Sulforaphane causes a major epigenetic repression of myostatin in porcine satellite cells. Epigenetics. 7:1379–1390. 2012. View Article : Google Scholar : PubMed/NCBI
53	Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W and Yang CS: Tea polyphenol (−)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 63:7563–7570. 2003.PubMed/NCBI
54	Lee WJ, Shim JY and Zhu BT: Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol. 68:1018–1030. 2005. View Article : Google Scholar : PubMed/NCBI
55	Kuck D, Caulfield T, Lyko F and Medina-Franco JL: Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol Cancer Ther. 9:3015–3023. 2010. View Article : Google Scholar : PubMed/NCBI
56	Caulfield T and Medina-Franco JL: Molecular dynamics simulations of human DNA methyltransferase 3B with selective inhibitor nanaomycin A. J Struct Biol. 176:185–191. 2011. View Article : Google Scholar : PubMed/NCBI
57	Akhavan-Niaki H and Samadani AA: DNA methylation and cancer development: Molecular mechanism. Cell Biochem Biophys. 67:501–513. 2013. View Article : Google Scholar : PubMed/NCBI
58	Gokul G and Khosla S: DNA methylation and cancer. Subcell Biochem. 61:597–625. 2013. View Article : Google Scholar
59	Shu XS, Li L and Tao Q: Chromatin regulators with tumor suppressor properties and their alterations in human cancers. Epigenomics. 4:537–549. 2012. View Article : Google Scholar : PubMed/NCBI
60	Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang FF, Villella J, Schneider A, Terry MB, Mansukhani M and Murty VV: Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: Its relationship to clinical outcome. Mol Cancer. 2:242003. View Article : Google Scholar : PubMed/NCBI
61	Kang S, Kim JW, Kang GH, Lee S, Park NH, Song YS, Park SY, Kang SB and Lee HP: Comparison of DNA hypermethylation patterns in different types of uterine cancer: Cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. Int J Cancer. 118:2168–2171. 2006. View Article : Google Scholar
62	Braggio E, Maiolino A, Gouveia ME, Magalhães R, Souto Filho JT, Garnica M, Nucci M and Renault IZ: Methylation status of nine tumor suppressor genes in multiple myeloma. Int J Hematol. 91:87–96. 2010. View Article : Google Scholar
63	Liu S, Ren S, Howell P, Fodstad O and Riker AI: Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res. 21:545–558. 2008. View Article : Google Scholar : PubMed/NCBI
64	Xu XL, Yu J, Zhang HY, Sun MH, Gu J, Du X, Shi DR, Wang P, Yang ZH and Zhu JD: Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol. 10:3441–3454. 2004.PubMed/NCBI
65	Ho AS, Turcan S and Chan TA: Epigenetic therapy: Use of agents targeting deacetylation and methylation in cancer management. Onco Targets Ther. 6:223–232. 2013.PubMed/NCBI
66	Wu CC, Chuang HY, Lin CY, et al: Inhibition of Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane. Mol Carcinog. 52:946–958. 2013. View Article : Google Scholar